Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure

This publication has 20 references indexed in Scilit:

• Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)
  Hypertension, 1996
• Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
  American Heart Journal, 1995
• Minimum heart rate and coronary atherosclerosis: Independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age
  American Heart Journal, 1992
• How important is heart rate?
  Journal Of Hypertension, 1991
• Ro 40–5967: A New Nondihydropyridine Calcium Antagonist
  Cardiovascular Drug Reviews, 1991
• Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II)
  The American Journal of Cardiology, 1990
• Effects of Ro 40-5967, a Novel Calcium Antagonist, on Myocardial Function During Ischemia Induced by Lowering Coronary Perfusion Pressure in Dogs: Comparison with Verapamil
  Journal of Cardiovascular Pharmacology, 1989
• The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
  New England Journal of Medicine, 1988
• Heart rate and cardiovascular mortality: The Framingham study
  American Heart Journal, 1987
• Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure
  The American Journal of Cardiology, 1985